Two‑Year Imaging Outcomes from a Phase 3 Randomized Trial of Secukinumab in Patients with Non‑Radiographic Axial Spondyloarthritis

Braun et al. studied a large cohort of patients with nr-axSpA, that demonstrated a secukinumab reduced SI joint inflammation (BME), this reduction was sustained over 104 weeks, from an overall low baseline level of spinal inflammation or structural damage.

In this paper a randomised, double-blind, placebo controlled, multicentre phase 3 study was conducted, evaluable patients were assessed, and a greater reduction was seen in patients with definite SI joint inflammation at baseline.